Martha Kim
Family · Henderson, NVNPI 1003491929
Payments from drug & device makers
Across 50 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$142
- AbbVie$121
- Novo Nordisk$105
- Amgen$96
- Novartis$75
- Tandem Diabetes Care, Inc.$66
- plus $613 from 22 others
What the payments were for
- Food & beverage$1,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 2 | $142 |
| AbbVie | 1 | $121 |
| Novo Nordisk | 5 | $105 |
| Amgen | 5 | $96 |
| Novartis | 2 | $75 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 4 | $65 |
| Pfizer | 3 | $64 |
| Abbott | 3 | $59 |
| Mannkind Corporation | 2 | $34 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $30 |
| Sequel Med Tech, LLC | 1 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Intra-sana Laboratories | 1 | $20 |
| Alvogen Inc | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| GSK | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$139
- UBRELVY$121
How this compares
$1,217 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $12,559 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $406 |
| Levothyroxine Sodium | 31 | $388 |
| Atorvastatin Calcium | 42 | $324 |
| Lisinopril | 33 | $271 |
| Losartan Potassium | 34 | $225 |
| Chlorthalidone | 14 | $168 |
| Hydrochlorothiazide | 23 | $100 |
| Alendronate Sodium | 11 | $99 |
| Metoprolol Succinate | 12 | $96 |
| Amlodipine Besylate | 19 | $71 |
| Metformin Hcl | 15 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $105 | $12,55914 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $38831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.
Other family in Henderson
- Kristy SolisHenderson$23K
- Joseph LauHenderson$18K
- Judith YuHenderson$14K
- Daniel Sam AciertoHenderson$11K
- Reiko TapiaHenderson$10K
- Francis TorresHenderson$8K
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.